2024 ASCO Annual Meeting Preview: The Show and After Show

The 2024 ASCO Annual Meeting promises to be a landmark event, brimming with groundbreaking research and the latest advancements in cancer care.

In the inaugural The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec offer a glimpse at some of the presentations guaranteed to spark one’s curiosity, spur debate, and enhance the field even further.

Of note, lung cancer clinical trials appear to be a hot topic to come out of this year’s meeting, including the phase 3 LAURA study (NCT03521154) designed to evaluate osimertinib (Tagrisso) after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC), as well as the phase 3 ADRIATIC trial (NCT03703297) of durvalumab (Imfinzi) as a consolidation therapy in patients with limited-stage small-cell lung cancer.

Additional trials that oncologists can keep their eye on include:

• the phase 3 NADINA trial (NCT04949113) of neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) compared with adjuvant nivolumab in resectable stage III melanoma;
• the phase 3 EVOKE-01 study (NCT05089734) of sacituzumab govitecan-hziy (Trodelvy) vs docetaxel for the treatment of previously treated NSCLC;
• the phase 3 PALOMA-3 trial (NCT05388669) of lazertinib with subcutaneous amivantamab (Rybrevant) compared to intravenous amivantamab in patients with EGFR-mutated advanced or metastatic NSCLC; and
• the phase 3 ARMANI trial (NCT02934464) of ramucirumab (Cyramza) plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction cancers.

ASCO 2024 isn't just about lectures, as the team also offers food recommendations, fun activities to partake in, as well as interesting facts about Chicago.

This is just a taste of the wealth of information and inspiration waiting at ASCO 2024. Check back for future meeting previews with The Show and After Show.